Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Evaluating the role of chemotherapy in triple-negative breast cancer

Hope Rugo • 14 Mar 2025
BCC 2025
Breast Cancer

Hope Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses on the need for chemotherapy in early-stage triple-negative breast cancer, suggesting that both tumor size and biology play a role in determining the need for chemotherapy. While T1a tumors generally have a good prognosis, T1b and T1c tumors require chemotherapy, with T1c being the most high-risk. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hope Rugo

Utilizing TILs to stratify treatment strategies in breast cancer
2:04
Utilizing TILs to stratify treatment strategies in breast cancer
Hope Rugo • 14 Mar 2025
Novel ADC and checkpoint inhibitor combinations in breast cancer
2:38
Novel ADC and checkpoint inhibitor combinations in breast cancer
Hope Rugo • 14 Mar 2025
What to look forward to in breast cancer at ASCO 2023
3:24
What to look forward to in breast cancer at ASCO 2023
Hope Rugo • 12 May 2023
Detailed safety analysis from the DESTINY-Breast04 trial
6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals